RxDoctor Payments Data

Anna Strongin, MD

Gastroenterology · Rockville, MDNPI 1255621363

Payments from drug & device makers

$4,499in general payments, 2019–2025

Across 233 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$526
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$491
  • Johnson & Johnson$439
  • Takeda Pharmaceuticals U.S.A., Inc.$280
  • Bristol Myers Squibb$227
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,38397%
  • Education$1163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,499 in reported general payments places this provider in the 55th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$109,178
Medicare patients
410
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide36$39,054
ClenpiqSod Picosulf/Mag Ox/Citric Ac52$8,901
Mesalamine11$7,175
Omeprazole263$3,490
Colestipol Hcl48$2,799
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates44$2,606
Famotidine153$1,940
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,734
Pantoprazole Sodium81$1,284
LoperamideLoperamide Hcl16$576
Dicyclomine Hcl63$544
Esomeprazole Magnesium13$474
Sucralfate14$422
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl21$275
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,162$39,05436 claims
Ferring Pharmaceuticals Inc.Clenpiq$79$8,90152 claims
Braintree Laboratories, Inc.Sutab$17$1,73411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →